Literature DB >> 6362940

Factors influencing susceptibility of LEW rats to Heymann nephritis.

B Noble, J B Van Liew, G A Andres, J R Brentjens.   

Abstract

Although most LEW rats develop the proteinuria of Heymann nephritis (HN) within 2 months after immunization with Fx1A, protein excretion of some animals remains normal. We have compared nonproteinuric rats with those that developed HN in order to identify factors that influence susceptibility to immunologically medicated kidney disease. In the primary response to Fx1A, immunofluorescence tests showed that antibrush border titers in serum and immunoglobulin deposition in vivo were similar in all rats. However, complement was detected only in rats with proteinuria. Reimmunization with Fx1A at 30 weeks stimulated anamnestic antibody responses in all rats. Following reimmunization, 60% of nonproteinuric rats developed severe HN with an unusually rapid (1 week) onset. Once again, complement was present only in glomeruli of rats with proteinuria. It appears that titers of antibodies to brush border, measured by immunofluorescence tests, are not an index of the pathogenicity of the immune response to Fx1A. Immunological memory, leading to rapid expression of autoimmune disease upon reexposure to antigen, can be established by a primary immunization that does not produce clinical symptoms. Abnormal urine protein composition may provide a clue to subclinical immunopathology of the kidney.

Entities:  

Mesh:

Year:  1984        PMID: 6362940     DOI: 10.1016/0090-1229(84)90059-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  16 in total

1.  Antibody-mediated proliferation of proximal tubule cells.

Authors:  M Brodkin; B Noble
Journal:  Clin Exp Immunol       Date:  1988-01       Impact factor: 4.330

2.  Passively transferred anti-brush border antibodies induce injury of proximal tubules in the absence of complement.

Authors:  B Noble; G A Andres; J R Brentjens
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

3.  A role for thromboxane in complement-mediated glomerular injury.

Authors:  A V Cybulsky; W Lieberthal; R J Quigg; H G Rennke; D J Salant
Journal:  Am J Pathol       Date:  1987-07       Impact factor: 4.307

4.  Mouse models of membranous nephropathy: the road less travelled by.

Authors:  Dorin-Bogdan Borza; Jun-Jun Zhang; Laurence H Beck; Catherine Meyer-Schwesinger; Wentian Luo
Journal:  Am J Clin Exp Immunol       Date:  2013-06-15

5.  Epitope specificity of anti-gp330 autoantibodies determines the development of proteinuria in active Heymann nephritis.

Authors:  E H Van Leer; P Ronco; P Verroust; A M van der Wal; P J Hoedemaeker; E De Heer
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

6.  Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Jord M Cowan; Chang Soon Yoon; David M Waisman; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

Review 7.  Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.

Authors:  P Ronco; H Debiec
Journal:  Semin Immunopathol       Date:  2007-09-26       Impact factor: 9.623

8.  Induction of Heymann nephritis with a gp330/megalin fusion protein.

Authors:  R Raychowdhury; G Zheng; D Brown; R T McCluskey
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

9.  Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex nephritis.

Authors:  C J Pruchno; M M Burns; M Schulze; R J Johnson; P J Baker; C E Alpers; W G Couser
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

10.  Genetic factors influence level of proteinuria in cationic antigen-induced immune complex glomerulonephritis in the rat.

Authors:  A Kato; F Thaiss; T Oite; E Günther; S Batsford; A Vogt
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.